Has the Game Changed?The old game was that retail investors took the initial risk to fund development companies. There were too many opportunities for institutional investors to make commitment. Wait until successful development companies started to emerge until to buy in. Use the institutional buying price to manage the market price down. When success comes, institutional investors own the controlling hand. Retail investors are treated as chumps despite having the initial vision.
The play on Oncolytics is buy and hold because Reolysin is going to a break through viral therapy. Sell if you do not believe. The research, trials, and US NCI endorsement does not support selling. In the last quarter of 2010, the NASDAQ reported an increase of institutional holdings from 20 companies to 34 companies with a net increase of shares of 8,141,527 shares. The institutional investors are coming on board for the big gain.
Retail investors, you loose if you sell. You win by holding and get bonus winnings if you participate in the buy side manipulation and buy more! Institutional investors, you loose if you do not acquire your desired position. Look at today’s trading, the buy side manipulation is not generating the volume of shares that you need. Their selling to depress the price was counter productive. Supply increases with price, eco 101.
Some institutional traders opened the market today with large sell orders: 45,000 shares on the NASDAQ and 18,000 on the TSX. Their objective was to spread fear to cause retail investors to panic and sell their shares. It did not happen. All that they accomplished was to set the daily lows of $5.70 and $5.26. Retail investors hold onto your shares the April 2009 story of Dendreon, DNDN on the Nasdaq, is going to be repeated with Oncolytics soon. Consider buying and using margin. Institutional investors are wise to recognize the risk of condoning the buy side manipulation and acquire their position quickly. Time is not your friend and you may not have enough time to buy. There will be more competition for shares as short sellers will need to cover their positions.
Here is table showing the trading of Dendreon in April 2009.
| Date | Closing Price | Volume |
| 1-Apr-09 | $4.14 | 3,199,650 |
| 2-Apr-09 | 4.34 | 2,427,867 |
| 3-Apr-09 | 5.99 | 22,497,200 |
| 6-Apr-09 | 6.58 | 19,585,750 |
| 7-Apr-09 | 6.58 | 7,346,062 |
| 8-Apr-09 | 6.37 | 5,392,639 |
| 9-Apr-09 | 6.30 | 4,234,697 |
| 13-Apr-09 | 7.30 | 12,775,310 |
| 14-Apr-09 | 16.99 | 65,120,890 |
| 15-Apr-09 | 17.17 | 19,294,060 |
| 16-Apr-09 | 17.03 | 6,894,881 |
| 17-Apr-09 | 17.99 | 17,799,470 |
| 20-Apr-09 | 19.52 | 17,724,250 |
| 21-Apr-09 | 19.74 | 11,008,510 |
| 22-Apr-09 | 20.12 | 7,358,435 |
| 23-Apr-09 | 20.33 | 6,123,418 |
| 24-Apr-09 | 20.08 | 7,393,327 |
| 27-Apr-09 | 21.55 | 18,569,850 |
| 28-Apr-09 | 11.81 | 28,070,740 |
| 29-Apr-09 | 22.94 | 48,235,790 |
| 30-Apr-09 | 21.20 | 17,468,950 |
| Friday Close | | |
| 11-Mar-11 | $33.80 | 2,036,250 |